Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05712889




Registration number
NCT05712889
Ethics application status
Date submitted
25/01/2023
Date registered
6/02/2023
Date last updated
12/01/2024

Titles & IDs
Public title
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Scientific title
An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity and Pharmacokinetics of VIP236 Monotherapy in Subjects With Advanced Cancer
Secondary ID [1] 0 0
VNC-236-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Neoplasms 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - VIP236

Experimental: Dose Escalation of VIP236 - Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer


Treatment: Drugs: VIP236
VIP236 will be administered by IV infusion once every 3 weeks.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of DLT (Dose limit toxicity) of VIP236
Timepoint [1] 0 0
Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 21 days
Primary outcome [2] 0 0
Number of participants with adverse events as a measure safety and tolerability
Timepoint [2] 0 0
Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 21 days (up to approximately 10 months)
Secondary outcome [1] 0 0
Disease control rate (DCR) per RECIST v1.1, defined as best overall response of complete response (CR), partial response (PR), or stable disease (SD) as determined by Investigator review.
Timepoint [1] 0 0
Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 21 days (up to approximately 10 months)
Secondary outcome [2] 0 0
Progression-free survival per RECIST v1.1, defined as the time from enrollment to documented disease progression or death from any cause, whichever occurs earlier as determined by Investigator review
Timepoint [2] 0 0
Up to 24 months
Secondary outcome [3] 0 0
Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of VIP236
Timepoint [3] 0 0
Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 21 days
Secondary outcome [4] 0 0
Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of VIP236
Timepoint [4] 0 0
Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 21 days

Eligibility
Key inclusion criteria
- Adult patients aged >/=18 years, able to provide informed consent and willing to
comply with all study procedures.

- Histologically confirmed advanced or metastatic solid tumors that are relapsed or
refractory to standard of care. Subjects must have exhausted all available standard
therapies or be deemed ineligible for potential available therapies.

- Adequate bone marrow, liver, and renal functions.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Subjects who have new or progressive brain or meningeal or spinal metastases.

- Clinically significant cardiac disease including congestive heart failure > New York
Heart Association (NYHA) Class II), evidence for coronary artery disease (eg, unstable
angina (anginal symptoms at rest) or new-onset angina (within the last 6 months or
myocardial infarction within the past 6 months before first dose.

- Major surgery or significant trauma within 4 weeks before the first dose of study
drug.

- Medical history of chronic obstructive pulmonary disease (COPD) and other respiratory
disorders.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/01/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2024
Actual
Sample size
Target
24
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,Southern Australi
Recruitment hospital [1] 0 0
Macquarie University - Macquarie Park
Recruitment hospital [2] 0 0
ICON Brisbane - Brisbane
Recruitment hospital [3] 0 0
ICON Adelaide - Adelaide
Recruitment postcode(s) [1] 0 0
2109 - Macquarie Park
Recruitment postcode(s) [2] 0 0
4101 - Brisbane
Recruitment postcode(s) [3] 0 0
5037 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Texas

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Vincerx Pharma, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered
VIP236 as monotherapy in patients with advanced solid tumor cancer
Trial website
https://clinicaltrials.gov/ct2/show/NCT05712889
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Vincerx Study Director
Address 0 0
Vincerx Pharma, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Vincerx Clinical Trials Contact
Address 0 0
Country 0 0
Phone 0 0
1-650-800-6676
Fax 0 0
Email 0 0
clinicaltrials@vincerx.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05712889